PAK1 and neoplasm: Our results provide additional rationale for combination mTOR/MEK inhibitor therapy because in addition to the anti-proliferative effects of MEK inhibitor treatment, mTOR inhibition resulting in enhanced PAK1/JNK/FOXO3-mediated apoptosis could inhibit tumor progression.